Corvus Pharmaceuticals, Inc.
CRVS
$6.93
-$0.32-4.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -99.57% | -66.55% | -130.47% | -88.24% | 42.04% |
| Total Depreciation and Amortization | -9.80% | -28.21% | -43.71% | -57.14% | -63.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 452.75% | 197.11% | 487.90% | 261.25% | -77.93% |
| Change in Net Operating Assets | 227.99% | -52.90% | 54.17% | 90.48% | -41.94% |
| Cash from Operations | -35.72% | -35.98% | -6.22% | 15.92% | 23.63% |
| Capital Expenditure | -- | -- | -- | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,033.90% | -312.25% | -276.49% | -269.55% | -805.95% |
| Cash from Investing | -1,040.21% | -312.53% | -276.85% | -269.70% | -331.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 226.80% | 350.16% | 346.38% | 109.48% | 122.61% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -- | -- | -- | -- |
| Cash from Financing | 78.17% | 528.03% | 524.16% | 287.27% | 308.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -102.09% | -11.78% | -619.85% | -244.08% | 134.50% |